EFFICACY & SFTY OF SHRT CORSE ANTIRETROVIRAL THRPY FOR ACUTE OR RECNT HIV-1 INF

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究是为了了解在艾滋病毒感染早期治疗是否有益。换句话说，这项研究将评估抗艾滋病毒药物(埃米拉宾加替诺福韦(Truvada)和洛匹那韦(Lopinavir)加利托那韦(Kaletra))对最近感染艾滋病毒的人的安全性和有效性。众所周知，联合抗艾滋病毒药物可以降低血液中的病毒数量(病毒载量)，改善免疫系统。然而，这些药物也有短期和长期的副作用，在人们决定是否开始抗艾滋病毒药物时也会考虑这些副作用。随着我们对抗艾滋病毒药物及其好的和坏的影响有了更多的了解，艾滋病毒治疗专家关于何时开始抗艾滋病毒药物的意见确实发生了变化。这项研究中使用的三种药物已获得美国食品和药物管理局(FDA)的批准，用于治疗慢性艾滋病毒感染者。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to learn if treating people during early HIV infection is beneficial. In other words, this study will evaluate how safe and effective a combination of anti-HIV drugs (emcitrabine plus tenofovir (Truvada) and lopinavir plus ritonavir (Kaletra) is for people with recently acquired HIV infection. It is known that combination anti-HIV drugs decreases the amount of virus in the blood (viral load) and improve the immune system. However, these drugs also have short-term and long-term side effects that are also considered when people decide whether or not to begin anti-HIV medicine. The opinions of HIV treatment experts regarding when to start anti-HIV medicine do change as we learn more about the anti-HIV drugs and their good and bad effects over time. The three drugs used in this study have been approved of by the U.S. Food and Drug Administration for the treatment of people with chronic HIV infection.